Patients who would have been candidates for NAC before COVID-19—including patients with TNBC, HER2-positive, and genomic high-risk (MammaPrint)/clinical high-risk hormone receptor–positive/HER2 negative breast cancer—remain so. This evidence concerns the gene NR4A1 and breast carcinoma.